Trial Profile
Early treatment with deferasirox (Exjade®) in low risk MDS
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2013
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms Exjade-Early-Trial
- 11 Aug 2012 Actual end date (17 Jul 2012) added as reported by European Clinical Trials Database record.
- 17 Jul 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 12 Oct 2011 New trial record